Table 2. Demographic data from all two cohorts of respondents for medical and clinical oncologists.

Covariate	Clinical oncology cohort (n=48), n [%]	Medical oncology cohort (n=85), n [%]	P value
Based on your best estimate how many new patients with primary lung cancers do you see in a month?			0.42
<5 cases	18 [40]	28 [35]
5–15 cases	24 [53]	41 [51]
>15 cases	3 [7]	12 [15]
Missing	3	4
Based on your best estimate what proportion of the lung cancer patients in your practice have drug targetable EGFR mutations?			0.11
<10%	10 [22]	26 [32]
10–30%	22 [49]	44 [54]
>30%	13 [29]	11 [14]
Missing	3	4
Based on your best estimate what proportion of the lung cancer patients in your practice have drug targetable ALK mutations?			0.5
<5%	32 [71]	65 [80]
5–10%	11 [24]	14 [17]
>10%	2 [4]	2 [2]
Missing	3	4
Based on your best estimate what proportion of the lung cancer patients in your practice have drug targetable BRAF MET RET or ROS1 mutations?			0.45
<5%	40 [91]	77 [95]
5–10%	4 [9]	4 [5]
>10%	0 [0]	0 [0]
Missing	4	4
Access to tyrosine kinase inhibitors EGFR specific in your practice environment?			N/A
Yes	36 [100]	28 [100]
Missing	12	57
Access to tyrosine kinase inhibitors ALK specific in your practice environment?			0.0019*
Yes	21 [58]	26 [93]
No	15 [42]	2 [7]
Missing	12	57

*, P<0.05. Missing, data not available (i.e., no response in questionnaire); EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; N/A, P value not calculated.